Abstract
Palifermin, (Kepivance), recombinant human keratinocyte growth factor, has been approved for treatment of patients with mucositis after high-dose chemotherapy followed by auto-SCT and/or irradiation.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
